Evidence map›Paper›PMID 40849364›Full record

ArticleBone marrow transplantation2025

The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

Timothy E O'Connor, Chenyu Lin, Gregory W Roloff, Amy Zhang, Katharine Miller, Ibrahim Aldoss, Noam E Kopmar, Simone E Dekker, Vishal K Gupta, Nikeshan Jeyakumar and 54 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

64 authors.

Timothy E O'Connor *Loyola University Medical Center, Maywood, IL, USA.
Chenyu Lin *Duke University, Durham, NC, USA.ORCID 0000-0002-4542-4232
Gregory W RoloffUniversity of Chicago, Chicago, IL, USA.
Amy ZhangStanford University School of Medicine, Stanford, CA, USA.
Katharine MillerStanford University School of Medicine, Stanford, CA, USA.
Ibrahim AldossCity of Hope National Medical Center, Duarte, CA, USA.
Noam E KopmarFred Hutchinson Cancer Center & University of Washington School of Medicine, Seattle, WA, USA.
Simone E DekkerFred Hutchinson Cancer Center & University of Washington School of Medicine, Seattle, WA, USA.
Vishal K GuptaUniversity of California Los Angeles, Los Angeles, CA, USA.
Nikeshan JeyakumarStanford University School of Medicine, Stanford, CA, USA.
Ibrahim N MuhsenCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
Yannis ValtisMemorial Sloan Kettering Cancer Institute, New York City, NY, USA.
Naveed AhmedMemorial Sloan Kettering Cancer Institute, New York City, NY, USA.
Katherine SutherlandStanford University School of Medicine, Stanford, CA, USA.
Kaitlyn C DykesUniversity of California San Diego, La Jolla, CA, USA.
Mohamed AhmedCedars-Sinai Medical Center, Los Angeles, CA, USA.
Evan ChenDana Farber Cancer Institute - Harvard Medical School, Boston, MA, USA.
Hector ZambranoSarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center - HCT Healthcare, Nashville, TN, USA.
Danielle BradshawAugusta University - Georgia Cancer Center, Augusta, GA, USA.
Santiago MercadalUniversity of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
Marc SchwartzUniversity of Colorado, Aurora, CO, USA.
Sean TracyUniversity of Minnesota, Minneapolis, MN, USA.
Matthew P ConnorUniversity of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-1186-0623
Michal KubiakBillings Clinic, Billings, MT, USA.
Akash MukherjeeUniversity of Arkansas for Medical Sciences, Little Rock, AR, USA.
Navneet MajhailSarah Cannon Cancer Institute, Nashville, TN, USA.ORCID 0000-0001-7082-891X
Minoo BattiwallaSarah Cannon Cancer Institute, Nashville, TN, USA.
Luke MountjoyColorado Blood Cancer Institute, Denver, CO, USA.
Shahbaz A MalikTexas Transplant Institute, Austin, TX, USA.
John MathewsSarah Cannon Transplant and Cellular Therapy Program, Dallas, TX, USA.
Paul ShaughnessySarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital, San Antonio, TX, USA.
Betsy BlunkSarah Cannon Cancer Institute, Nashville, TN, USA.
Aaron C LoganUniversity of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1179-5879
Abdullah LadhaUniversity of Southern California, Los Angeles, CA, USA.
Anjali S AdvaniCleveland Clinic, Cleveland, OH, USA.ORCID 0000-0003-0015-5902
Maryann StefanCleveland Clinic, Cleveland, OH, USA.
Caitlin GuzowskiNorthside Hospital Cancer Institute, Atlanta, GA, USA.
Rasmus T HoegUniversity of California Davis, Davis, CA, USA.
Talal HilalMayo Clinic Arizona, Phoenix, AZ, USA.
Jozal MooreUniversity of Rochester, Rochester, NY, USA.ORCID 0000-0003-4811-5790
Kristen M O'DwyerUniversity of Rochester, Rochester, NY, USA.
LaQuisa C HillCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0003-4304-935X
Joshua SasineCedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0001-9866-462X
Caspian OliaiUniversity of California Los Angeles, Los Angeles, CA, USA.
Melhem M SolhNorthside Hospital Cancer Institute, Atlanta, GA, USA.ORCID 0000-0003-3766-5623
Catherine J LeeUniversity of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.ORCID 0000-0003-2587-8955
Vamsi K KotaAugusta University - Georgia Cancer Center, Augusta, GA, USA.
Divya KouraUniversity of California San Diego, La Jolla, CA, USA.
Muthu V KumaranUniversity of Arkansas for Medical Sciences, Little Rock, AR, USA.
Jessica T LeonardOregon Health & Science University, Portland, OR, USA.ORCID 0000-0001-5576-0048
Noelle V FreyUniversity of Pennsylvania, Philadelphia, PA, USA.
Jae H ParkMemorial Sloan Kettering Cancer Institute, New York City, NY, USA.
Marlise R LuskinDana Farber Cancer Institute - Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5781-4529
Veronika BachanovaUniversity of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-9325-432X
Ahmed GalalDuke University, Durham, NC, USA.
Vinod PullarkatCity of Hope National Medical Center, Duarte, CA, USA.ORCID 0000-0001-9129-3424
Michael R BishopUniversity of Chicago, Chicago, IL, USA.
Wendy StockUniversity of Chicago, Chicago, IL, USA.
Ryan D CassadayFred Hutchinson Cancer Center & University of Washington School of Medicine, Seattle, WA, USA.ORCID 0000-0002-3424-2425
Bijal D ShahH. Lee Moffitt Cancer Center, Tampa, FL, USA.
Rawan FaramandH. Lee Moffitt Cancer Center, Tampa, FL, USA.
Lori S MufflyStanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-9887-6136
Stephanie B TsaiLoyola University Medical Center, Maywood, IL, USA.
Bhagirathbhai DholariaVanderbilt University Medical Center, Nashville, TN, USA. Bhagirathbhai.R.Dholaria@vumc.org.ORCID 0000-0003-2371-3655

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
TRAINING IN CANCER BIOLOGY &TRANSPLANTATIONT32CA009515 · NCI · UNIVERSITY OF WASHINGTON · PI NANCY ELLEN DAVIDSON, Effie W Petersdorf · 1985 to 2026
$16.2M
TRANSFUSION MEDICINE AND RELATED AREAST32HL007057 · NHLBI · DUKE UNIVERSITY · PI Gowthami M Arepally · 1985 to 2026
$10.6M
NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA009515NHLBI NIH HHS T32 HL007057
6 · The paper itself

Abstract

Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T (CAR T) cell therapy approved for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We studied the impact of social determinants of health (SDoH) on outcomes of adults with B-ALL receiving brexu-cel. This retrospective analysis included adults (≥18 years) with R/R B-ALL treated with brexu-cel between 2021 and 2023. Cox proportional hazards models evaluated the association of race, ethnicity, and SDoH with progression-free survival (PFS) and overall survival (OS). 189 patients received brexu-cel and 57% were male. 55% were non-Hispanic White, 30% Hispanic, 7% non-Hispanic Black, 6% Asian/Pacific Islander, and 2% other/unknown. 43% were referred from private/community-based practices and 35% lived 50 miles or greater from the CAR T center. Health insurance included public (47%) and private (41%). 31% had a high social deprivation index (SDI, 76-99th percentile). Black race was associated with worse OS (HR 3.48; 95% CI 1.01-12.03). There was no difference in PFS (HR 1.03, 95% CI 0.50-2.10) or OS (HR 1.43; 95% CI 0.56-3.65) in Hispanic patients. Outcomes appear independent of SDoH and SDoH did not impact OS. We observed comparable outcomes to non-Hispanic patients.

Indexed as

Immunotherapy, AdoptivePrecursor B-Cell Lymphoblastic Leukemia-LymphomaSocial Determinants of HealthAdolescentAdultAgedFemaleHumansMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaRecurrenceRetrospective StudiesYoung Adult

Identifiers

PMID40849364
PMCPMC12583187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.